WO2003103709A3 - MODULATION OF BONE DEVELOPMENT - Google Patents

MODULATION OF BONE DEVELOPMENT Download PDF

Info

Publication number
WO2003103709A3
WO2003103709A3 PCT/CA2003/000823 CA0300823W WO03103709A3 WO 2003103709 A3 WO2003103709 A3 WO 2003103709A3 CA 0300823 W CA0300823 W CA 0300823W WO 03103709 A3 WO03103709 A3 WO 03103709A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulation
bone development
development
bone
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/000823
Other languages
French (fr)
Other versions
WO2003103709A2 (en
Inventor
Reginald M Gorczynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Trillium Therapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trillium Therapeutics ULC filed Critical Trillium Therapeutics ULC
Priority to EP03727091A priority Critical patent/EP1532176A2/en
Priority to AU2003233721A priority patent/AU2003233721B2/en
Priority to JP2004510828A priority patent/JP4763282B2/en
Priority to CA002487428A priority patent/CA2487428A1/en
Priority to US10/515,332 priority patent/US20050287603A1/en
Publication of WO2003103709A2 publication Critical patent/WO2003103709A2/en
Publication of WO2003103709A3 publication Critical patent/WO2003103709A3/en
Anticipated expiration legal-status Critical
Priority to US12/394,621 priority patent/US20090214573A1/en
Priority to AU2009217461A priority patent/AU2009217461A1/en
Priority to US13/084,009 priority patent/US20110189201A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods and compositions for modulating bone development are described.
PCT/CA2003/000823 2002-06-07 2003-06-06 Modulation of bone development Ceased WO2003103709A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP03727091A EP1532176A2 (en) 2002-06-07 2003-06-06 Cd200-receptor mediated modulation of bone development
AU2003233721A AU2003233721B2 (en) 2002-06-07 2003-06-06 CD200-receptor mediated modulation of bone development
JP2004510828A JP4763282B2 (en) 2002-06-07 2003-06-06 How to control bone development
CA002487428A CA2487428A1 (en) 2002-06-07 2003-06-06 Cd200-receptor mediated modulation of bone development
US10/515,332 US20050287603A1 (en) 2002-06-07 2003-06-06 Modulation of bone development
US12/394,621 US20090214573A1 (en) 2002-06-07 2009-02-27 Modulation of bne development
AU2009217461A AU2009217461A1 (en) 2002-06-07 2009-09-23 CD200-receptor mediated modulation of bone development
US13/084,009 US20110189201A1 (en) 2002-06-07 2011-04-11 Modulation of bone development

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38656402P 2002-06-07 2002-06-07
US60/386,564 2002-06-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/394,621 Continuation US20090214573A1 (en) 2002-06-07 2009-02-27 Modulation of bne development

Publications (2)

Publication Number Publication Date
WO2003103709A2 WO2003103709A2 (en) 2003-12-18
WO2003103709A3 true WO2003103709A3 (en) 2004-04-08

Family

ID=29736181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/000823 Ceased WO2003103709A2 (en) 2002-06-07 2003-06-06 Modulation of bone development

Country Status (6)

Country Link
US (3) US20050287603A1 (en)
EP (1) EP1532176A2 (en)
JP (3) JP4763282B2 (en)
AU (2) AU2003233721B2 (en)
CA (1) CA2487428A1 (en)
WO (1) WO2003103709A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
AU2003299823A1 (en) * 2002-12-27 2004-07-29 Schering Corporation Methods of inducing and maintaining immune tolerance
WO2008089022A2 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
US8647871B2 (en) * 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
WO2014113704A2 (en) 2013-01-18 2014-07-24 Escape Therapeutics, Inc. Enhanced differentiation of mesenchymal stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017543A2 (en) * 1999-09-03 2001-03-15 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2002020718A2 (en) * 2000-09-05 2002-03-14 The Rockefeller University Osteoclast-associated receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
NZ553470A (en) * 2002-03-15 2008-10-31 Schering Corp Methods of modulating CD200 receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017543A2 (en) * 1999-09-03 2001-03-15 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2002020718A2 (en) * 2000-09-05 2002-03-14 The Rockefeller University Osteoclast-associated receptor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GORCZYNSKI R M: "Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 31, August 2001 (2001-08-01), pages 2331 - 2337, XP002965417, ISSN: 0014-2980 *
GORCZYNSKI REGINALD M ET AL: "CD200 immunoadhesin suppresses collagen-induced arthritis in mice", CLINICAL IMMUNOLOGY (ORLANDO), vol. 101, no. 3, December 2001 (2001-12-01), pages 328 - 334, XP002264320, ISSN: 1521-6616 *
GORCZYNSKI REGINALD M ET AL: "CD200Fc and anti-CD200R regulates collagen induced arthritis (CIA) in mice", FASEB JOURNAL, vol. 16, no. 5, 22 March 2002 (2002-03-22), Annual Meeting of Professional Research Scientists on Experimental Biology;New Orleans, Louisiana, USA; April 20-24, 2002, pages A1045, XP009022374, ISSN: 0892-6638 *
HOEK-RM ET AL.: "Down-regulation of the macrophage lineage through interaction with OX2 (CD200)", SCIENCE, vol. 290, no. 5497, 1 December 2000 (2000-12-01), pages 1768 - 1771, XP002263649 *
KONG Y Y ET AL: "Molecular control of bone remodeling and osteoporosis", EXPERIMENTAL GERONTOLOGY, ELSEVIER SCIENCE, OXFORD, GB, vol. 35, no. 8, October 2000 (2000-10-01), pages 947 - 956, XP002233423, ISSN: 0531-5565 *
See also references of EP1532176A2 *
THEILL LARS E ET AL: "RANK-L and RANK: T cells, bone loss, and mammalian evolution.", ANNUAL REVIEW OF IMMUNOLOGY. UNITED STATES 2002, vol. 20, 2002, pages 795 - 823, XP001156511, ISSN: 0732-0582 *

Also Published As

Publication number Publication date
JP2006501167A (en) 2006-01-12
JP2010155843A (en) 2010-07-15
US20090214573A1 (en) 2009-08-27
WO2003103709A2 (en) 2003-12-18
AU2003233721B2 (en) 2009-07-02
US20110189201A1 (en) 2011-08-04
EP1532176A2 (en) 2005-05-25
AU2003233721A1 (en) 2003-12-22
CA2487428A1 (en) 2003-12-18
US20050287603A1 (en) 2005-12-29
JP2010285448A (en) 2010-12-24
AU2009217461A1 (en) 2009-10-15
JP4763282B2 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
NO20072302L (en) Hepatocyte growth factor activator modulators
EP1633311A4 (en) COMPOSITIONS AND METHODS FOR MODULATING S-NITROSOGLUTATHION REDUCTASE
WO2004078995A3 (en) Methods of modulating and of identifying agents that modulate intracellular calcium
CR9869A (en) ACTIVE COMPOUNDS IN PPAR
NO20043590L (en) Compositions and Methods for Modulating Connexin Hemic Channels
GB2423935B (en) Bone plates
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
MXPA05000655A (en) Methods and compositions for modulating t helper (th.
AR038563A1 (en) ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS
WO2004047749A3 (en) Purinergic modulation of smell
NO20071309L (en) Method of expansion
EA199900162A1 (en) INHIBITORS OF CELLULAR ADHESION
IS7721A (en) Piperidine-pyridazone and thalasone which inhibit PDE4
DK1877390T3 (en) Benzisoxazole-piperazine Compounds and Methods for Using Them
CY1113083T1 (en) CALCIUM COMPOUNDS
SG148182A1 (en) Antiloading compositions and methods of selecting same
EP1509250A4 (en) Methods compositions and articles of manufacture for modulating bone growth
NO20075140L (en) Methods and Preparations for Modulating Vascular Integrity
MY162181A (en) Compositions and methods for modulating hemostasis
EA200701293A1 (en) THERAPEUTIC COMPOSITION OF THE GROWTH FACTOR OF KERATINOCYTES
ATE433458T1 (en) SHIP-1 MODULATORS
ATE507209T1 (en) REFERENCE STANDARD FOR CHARACTERIZATION OF ROSUVASTATIN
WO2003103709A3 (en) MODULATION OF BONE DEVELOPMENT
ATE527280T1 (en) FLUORESCENT PROTEIN AND CHROMEPROTEIN
AU2003222426A1 (en) Methods and compositions for modulating beta-catenin phosphorylation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2487428

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004510828

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003233721

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003727091

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003727091

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10515332

Country of ref document: US